Pharma Attacked For “Playing The System” Of EU Pediatric Rewards
Executive Summary
As a public consultation on the impact of the EU Paediatric Regulation comes to an end, the French drug bulletin Prescrire has attacked pharma firms for taking advantage of the rewards and incentives provided in the regulation and paying only lip service to the need for new medicines for children.
You may also be interested in...
MEPs And Health Advocates Pile The Pressure On EU Drug Pricing
A European Parliament committee has approved a report outlining some possible solutions to the question of access to expensive new drugs, while Health Action International and several other NGOs have put emphasis on the need to ensure that where drugs developed by private companies use publicly funded research, they really serve the public good.
Is €20m A Reasonable Cost For An EU PIP? Consultation On Pediatric Rule
Biosimilars, the complicated rewards system, and the costs for companies involved in carrying out a pediatric investigation plan are among the many issues discussed in the European Commission’s newly released consultation on the Paediatric Regulation nearly 10 years after it came into force.
MEPs Slate EU Industry Practices In Report On Barriers To Medicines Access
The European Parliament’s environment and public health committee has produced a set of recommendations for a new approach to tackling barriers to medicines in the EU. There’s a particular focus on pricing strategies, intellectual property, and delays to generic competition.